Climaco John M 4
4 · CNS Pharmaceuticals, Inc. · Filed May 1, 2023
Insider Transaction Report
Form 4
Climaco John M
DirectorChief Executive Officer
Transactions
- Exercise/Conversion
Common Stock
2023-04-28+1,250→ 46,260 total - Exercise/Conversion
Restricted Stock Units
2023-04-28−1,250→ 60,201 total→ Common Stock (1,250 underlying)
Footnotes (2)
- [F1]Restricted stock units convert into common stock on a one-for-one basis.
- [F2]On April 28, 2022, the reporting person received 20,000 restricted stock units vesting as follows, subject to the grantee's continued service to the Company on each vesting date, (i) 25% of the grant will vest in four equal annual installments over 4 years; (ii) 25% of the grant will vest if within 24 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $2.00 (subject to pro rata adjustment for stock splits or similar events); (iii) 25% of the grant will vest if within 36 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $4.00 (subject to pro rata adjustment for stock splits or similar events); and (iv) 25% of the grant will vest if within 24 months from issuance the Issuer achieves positive interim, clinical data as determined by its Board of Directors.